Milvexian
Milvexian is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target plasma kallikrein, coagulation factor XI, and chymotrypsin-C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | 1 | 1 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | 1 | — | — | 2 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | 1 | — | — | 2 |
| Cerebral infarction | D002544 | — | I63 | — | — | 1 | — | — | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | — | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Thrombosis | D013927 | — | — | 9 | — | — | — | — | 9 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Factor xi deficiency | D005173 | — | D68.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Milvexian |
| INN | milvexian |
| Description | Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery. In 2018–2023, Bristol-Myers Squibb studied milvexian for the prevention of stroke.
|
| Classification | Small molecule |
| Drug class | coagulation factor XIa inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 1802425-99-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4112929 |
| ChEBI ID | — |
| PubChem CID | 118277544 |
| DrugBank | DB16233 |
| UNII ID | 0W79NDQ608 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KLKB1
KLKB1
F11
F11
CTRC
CTRC
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 141 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use